Clopidogrel News and Research

RSS

Clopidogrel is an oral antiplatelet agent (thienopyridine class) to inhibit blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease.

Cell-coated stent as effective as drug-coated ones

A stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents in keeping arteries open in coronary heart disease patients, according to two research studies presented at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

Tailored anti-clotting medications reduce adverse effects after percutaneous coronary intervention

Individually tailored anti-clotting medication dosing significantly cut the rate of adverse events after non-emergent percutaneous coronary intervention (PCI) with stenting, researchers reported at the American Heart Association's Scientific Sessions 2008. Results of the Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Stent Thrombosis study were presented as a late-breaking clinical trial.

11 Nov 2008

New devices used to reduce arterial occlusions, provide cardiac support

Research results highlighting three new devices used to reduce blockages in peripheral and coronary arteries and to provide cardiac support will be presented at the 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

12 Oct 2008

Triple cocktail of medicines to tackle stroke risk

Scientists at The University of Nottingham are to investigate whether giving recovering stroke patients a triple cocktail of medicines could reduce their chances of a further attack.

17 Sep 2008

Pre-hospital treatment on the way to percutaneous coronary intervention

For patients with acute ST-segment-elevation AMI (STEMI) within 12 hours after symptom onset and with persistent ST-segment elevation, or new or presumednew left bundle-branch block with concomitant ST-segment elevation, restoring coronary blood flow as early as possible is the main goal of reperfusion strategies.

2 Sep 2008

Safety of antithrombotic treatment in acute coronary syndromes

The management of acute coronary syndromes (with or without ST segment elevation) requires the use of anticoagulants, antiplatelet agents (aspirin, clopidogrel and/or glycoprotein (GP) IIb/IIIa inhibitors), beta-blockers, thrombolytics in some cases, and revascularization / reperfusion.

2 Sep 2008

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Data from a phase II study of an investigational drug designed to block formation of blood clots show potential for added protection against a second heart attack or stroke among patients who are already taking state-of-the-art prevention therapy.

2 Sep 2008

Overcoming poor response to standard oral antiplatelet agents

Existing practice surrounding many cardiovascular medications, including anti-hypertensive and lipid-lowering agents, is based on the evaluation of response to therapy. In cases where ideal therapeutic targets (which have been identified through several previous studies) are not met in the single individual, there is evidence to support the need to intensify standard treatment so as to achieve better control of the cardiovascular risk factor under treatment (e.g. blood pressure or cholesterol levels) as this translates into a better outcome.

2 Sep 2008

Two Penn studies show drug-eluting stents outperform bare metal stents

The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.

22 May 2008

Reducing blockage fails to improve access to the bloodstream for kidney dialysis

Reducing early blockages in bloodstream access for kidney failure treatment does not increase the likelihood that the access will function adequately for long-term treatments, according to a study funded by the National Institutes of Health. Results were published May 14, 2008, in the Journal of the American Medical Association.

22 May 2008

Study results on novel drug-eluting stent coated with a biodegradable polymer

"Real-world" use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry.

1 Apr 2008

Matrix registry probes adherence to clopidogrel at 1 year

A large community-based registry of patients treated with drug-eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors' orders to take clopidogrel, a drug that prevents unwanted blood clots; why they stop taking the drug; and the long-term consequences of that decision.

1 Apr 2008

Patients at risk of adverse events within 3 months after stopping certain ACS therapy

Patients who receive the anti-platelet medication clopidogrel following an acute coronary syndrome (such as heart attack) appear to be at greater risk of a heart attack or death in the first 90 days after stopping clopidogrel treatment, according to a study in the February 6 issue of JAMA: The Journal of the American Medical Association.

7 Feb 2008

Half of patients undergoing cerebrovascular stent placement do not respond well to clopidogrel

A study by researchers at Rush University Medical Center, published in the February issue of the American Journal of Neuroradiology, finds that half of patients undergoing cerebrovascular stent placement did not respond well to clopidogrel.

7 Feb 2008

Aspirin resistance and heart attack - stroke risk

Being resistant to aspirin makes patients four times more likely to suffer a heart attack, stroke or even die from a pre-existing heart condition, according to a study published on bmj.com.

21 Jan 2008

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

Daiichi Sankyo Company, Limited and Eli Lilly and Company have announced that on Wednesday, Dec. 26, 2007, they submitted a New Drug Application (NDA) for prasugrel to the U.S. Food and Drug Administration (FDA).

7 Jan 2008

The goals of platelet inhibition in acute coronary syndromes

Platelet activation and aggregation play important roles in the pathogenesis of cardiac ischemic events after either spontaneous plaque disruption in acute coronary syndromes or mechanical disruption of coronary artery plaques caused by percutaneous coronary intervention (PCI), which could be considered an artificially induced acute coronary syndrome.

3 Sep 2007

How to optimally prepare a patient for planned coronary angiography and subsequent angioplasty?

A Czech study compared two anti-clotting treatment regimens, currently used before coronary angiography / angioplasty to find the optimal balance between preventing ischemic versus bleeding complications of these procedures. The study was conducted in five Czech tertiary cardiology centers.

3 Sep 2007

Long-term treatment with anti-clotting drug clopidogrel improves stenting outcomes in diabetic patients

A study showing that diabetic patients who are treated with long-term anti-clotting therapy are less likely to have a heart attack or die more than a year after stenting has been named among the best research papers presented at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI).

18 May 2007

High-dose clopidogrel before stenting cuts heart attack risk in half

Pretreatment with double-dose anticlotting medication just before percutaneous coronary intervention (PCI) cuts the combined risk of heart attack and cardiac death by half, according to a study reported at the 30th Annual Scientific Sessions of the Society for Cardiovascular Angiography and Interventions (SCAI), May 9-12, 2007, in Orlando, FL.

15 May 2007

Clopidogrel News and Research

Cell-coated stent as effective as drug-coated ones

Tailored anti-clotting medications reduce adverse effects after percutaneous coronary intervention

New devices used to reduce arterial occlusions, provide cardiac support

Triple cocktail of medicines to tackle stroke risk

Pre-hospital treatment on the way to percutaneous coronary intervention

Safety of antithrombotic treatment in acute coronary syndromes

Factor Xa inhibitor Apixaban and antiplatelet therapy after acute coronary syndrome

Overcoming poor response to standard oral antiplatelet agents

Two Penn studies show drug-eluting stents outperform bare metal stents

Reducing blockage fails to improve access to the bloodstream for kidney dialysis

Study results on novel drug-eluting stent coated with a biodegradable polymer

Matrix registry probes adherence to clopidogrel at 1 year

Patients at risk of adverse events within 3 months after stopping certain ACS therapy

Half of patients undergoing cerebrovascular stent placement do not respond well to clopidogrel

Aspirin resistance and heart attack - stroke risk

Daiichi Sankyo, Lilly submit NDA for investigational antiplatelet drug, Prasugrelin U.S.

The goals of platelet inhibition in acute coronary syndromes

How to optimally prepare a patient for planned coronary angiography and subsequent angioplasty?

Long-term treatment with anti-clotting drug clopidogrel improves stenting outcomes in diabetic patients

High-dose clopidogrel before stenting cuts heart attack risk in half

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News